Why Use the 6-Minute Walk Test and NT-proBNP in PAH?
At a Glance
In PAH, the 6-minute walk test shows how well you manage physical activity, while NT-proBNP signals strain on the heart. Tracking both over time helps your care team detect silent worsening and adjust treatment; one abnormal result does not tell the whole story.
In this answer
4 sections
In pulmonary arterial hypertension (PAH), the disease can sometimes worsen silently before you start feeling more breathless or tired. To help catch these changes early, your care team relies on routine serial testing. The 6-minute walk test (6MWT) measures your functional exercise capacity—a useful proxy for how well your heart and lungs handle physical effort [1]. Meanwhile, the NT-proBNP blood test checks for chemical signs of cardiac stress [2]. Together, these tests provide objective clues about how well your treatment is working, helping your doctor adjust your medications based on your individual trends.
Catching Silent Progression Early
PAH forces the right ventricle—the heart’s lower-right pumping chamber—to work harder to push blood through narrowed arteries in your lungs. However, the heart is very good at compensating for this extra workload for a time. Because of this, you might feel perfectly fine even if the pressure in your lungs is slowly increasing or your heart is beginning to struggle.
By repeating tests on a regular schedule—often every 3 to 6 months, or more frequently if your treatment recently changed—doctors can track your individual trends [3]. These regular checks help estimate your overall risk of future complications, a process called risk assessment [4]. Identifying a worsening trend can prompt your care team to re-evaluate your treatment plan [5].
The 6-Minute Walk Test: A Standardized Proxy for Function
The 6-minute walk test (6MWT) is a supervised, standardized assessment performed in a clinic corridor. You are asked to walk as far as you can in six minutes, and the total distance you achieve is your 6-minute walk distance (6MWD).
During the test, staff will monitor your heart rate, oxygen saturation, and symptoms. You are allowed to slow down or rest if needed, and you should always report alarming symptoms like chest pain or severe dizziness so the test can be stopped safely. If you normally use supplemental oxygen, you will use it during the test unless your team instructs otherwise.
- What it tells us: A stable or improving walk distance compared to your last test suggests your body is tolerating the workload well [6].
- What to watch for: A shorter or decreasing distance over time can be an early indicator that your disease is progressing [1].
Keep in mind that the 6MWT is influenced by many factors. Things like age, arthritis, a recent cold, or simply having a bad day can lower your distance [7]. An isolated drop in distance does not automatically mean your PAH is worsening [8].
NT-proBNP: Detecting Cardiac Wall Stress
NT-proBNP (N-terminal pro–B-type natriuretic peptide) is a protein released into your blood when the heart muscle is stretched or stressed [2].
- Why it matters: In established PAH, elevated NT-proBNP levels can act as an indirect marker that the right ventricle is struggling against the high pressure in your lungs [9].
- Tracking your numbers: Dropping or maintaining a low NT-proBNP level suggests your heart is handling the pressure well, which is associated with better long-term survival [10]. Conversely, rising levels tell your team that your heart may be under increasing stress [1].
However, NT-proBNP is not a direct measurement of lung pressure and is not exclusively specific to the right side of the heart. Kidney function, age, irregular heart rhythms, and other health conditions can affect your results [11]. For the most accurate comparisons, it is best to have this blood test done at the same laboratory each time.
Better Together
Neither test tells the whole story on its own [12][13]. Doctors combine your 6MWD and NT-proBNP results with your symptoms, physical exam, and sometimes echocardiography (heart ultrasound) to estimate your risk category [14][15].
This multidimensional approach is a more complete way to assess risk and treatment response than looking at a single number [5]. We understand that frequent testing can feel stressful. However, keeping scheduled monitoring visits helps your team identify important changes. If transportation, cost, or other barriers make it hard to attend, please discuss this with your clinic so they can help.
🚨 When to Call Your Doctor Immediately
Do not wait for your next scheduled walk test or blood draw if you feel worse. Contact your PAH team or seek emergency care immediately if you experience:
- New or rapidly worsening breathlessness
- Fainting or near-fainting (syncope)
- Chest pain
- Rapid, unexplained weight gain or marked swelling in your legs/abdomen
- Blue or gray tint to your lips or fingers
Common questions in this guide
Why do doctors use both the 6-minute walk test and NT-proBNP for PAH?
What does a shorter 6-minute walk distance mean?
What can a high or rising NT-proBNP level mean in PAH?
How often are the 6-minute walk test and NT-proBNP repeated?
When should I contact my PAH team before the next test?
Related questions
Show more
Get notified when new evidence is published on Idiopathic/heritable pulmonary arterial hypertension.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (15)
- 1
The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension.
Wronski SL, Mordin M, Kelley K, et al.
Lung 2020; (198(1)):65-86 doi:10.1007/s00408-019-00289-2.
PMID: 31722043 - 2
BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing?
Lewis RA, Durrington C, Condliffe R, Kiely DG
European respiratory review : an official journal of the European Respiratory Society 2020; (29(156)) doi:10.1183/16000617.0009-2020.
PMID: 32414745 - 3
A pragmatic approach to risk assessment in pulmonary arterial hypertension using the 2015 European Society of Cardiology/European Respiratory Society guidelines.
Dardi F, Manes A, Guarino D, et al.
Open heart 2021; (8(2)) doi:10.1136/openhrt-2021-001725.
PMID: 34667092 - 4
Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model.
Hoeper MM, Kramer T, Pan Z, et al.
The European respiratory journal 2017; (50(2)) doi:10.1183/13993003.00740-2017.
PMID: 28775047 - 5
COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension.
Hoeper MM, Pausch C, Olsson KM, et al.
The European respiratory journal 2022; (60(1)) doi:10.1183/13993003.02311-2021.
PMID: 34737226 - 6
Idiopathic pulmonary arterial hypertension and co-existing lung disease: is this a new phenotype?
Peacock AJ, Ling Y, Johnson MK, et al.
Pulmonary circulation 2020; (10(1)):2045894020914851 doi:10.1177/2045894020914851.
PMID: 32284847 - 7
Baseline Sex Differences in Pulmonary Arterial Hypertension Randomized Clinical Trials.
Ventetuolo CE, Moutchia J, Baird GL, et al.
Annals of the American Thoracic Society 2023; (20(1)):58-66 doi:10.1513/AnnalsATS.202203-207OC.
PMID: 36053665 - 8
Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial.
Souza R, Channick RN, Delcroix M, et al.
PloS one 2018; (13(3)):e0193226 doi:10.1371/journal.pone.0193226.
PMID: 29590122 - 9
Right Atrial Function in Pulmonary Arterial Hypertension.
Querejeta Roca G, Campbell P, Claggett B, et al.
Circulation. Cardiovascular imaging 2015; (8(11)):e003521; discussion e003521 doi:10.1161/CIRCIMAGING.115.003521.
PMID: 26514759 - 10
Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis.
Hoeper MM, Pausch C, Olsson KM, et al.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2022; (41(7)):971-981 doi:10.1016/j.healun.2022.03.011.
PMID: 35430147 - 11
The Association of N-Terminal Pro-Brain Natriuretic Peptide With Time to Clinical Worsening in Hispanic Patients With Pulmonary Arterial Hypertension.
Khatab Y, Ghafouri SR, Alkhateeb H, et al.
Cardiology research 2022; (13(2)):73-80 doi:10.14740/cr1362.
PMID: 35465086 - 12
Six-minute walk test in pulmonary arterial hypertension.
Demir R, Küçükoğlu MS
Anatolian journal of cardiology 2015; (15(3)):249-54 doi:10.5152/akd.2015.5834.
PMID: 25880178 - 13
Risk stratification and treatment goals in pulmonary arterial hypertension.
Dardi F, Boucly A, Benza R, et al.
The European respiratory journal 2024; (64(4)) doi:10.1183/13993003.01323-2024.
PMID: 39209472 - 14
Evaluation of the European Society of Cardiology Risk Assessment Score in Incident Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.
Brown Z, Hansen D, Stevens W, et al.
Arthritis care & research 2024; (76(7)):973-983 doi:10.1002/acr.25328.
PMID: 38523256 - 15
Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension.
Benza RL, Kanwar MK, Raina A, et al.
Chest 2021; (159(1)):337-346 doi:10.1016/j.chest.2020.08.2069.
PMID: 32882243
This page is for informational purposes only and does not constitute medical advice. It explains how 6-minute walk testing and NT-proBNP may be used to monitor PAH; your PAH team should interpret your results in context.